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Abstract
Background: Estrogen signaling is mediated by estrogen receptor beta isoforms in normal and neoplastic human
testes. Recently, a G-protein-coupled-receptor (GPER) has been suggested as being involved in rapid responses to
estrogens in different normal and tumor cells.
Methods: This study investigated the GPER expression in paraffin-embedded samples from non neoplastic and
neoplastic human testes (sex-cord stromal and germ cell tumors) by immunohistochemical and Western Blot
analyses.
Results: In control testes, a positive GPER immunoreactivity was detected in Leydig and in Sertoli cells while all
germ cells were immunonegative. Furthermore, neoplastic cells of the Sertoli cell tumor, Leydig cell tumor,
seminoma and embryonal carcinoma samples were all immunopositive. The immunoblots of testis extracts
confirmed the results.
Conclusions: These findings suggest that GPER could mediate estrogen signaling in both normal and transformed
somatic cells of human testis, but they reveal a differential expression of the novel estrogen receptor in non
neoplastic and neoplastic germ cells.
Background
Estrogens exert their pleiotropic and tissue-specific
effects on target cells through the differential expression
of the classical estrogen receptors (ERs), ERa and ERb,
which mediate both genomic and rapid signaling events
[1,2]. In addition, estrogens induce rapid non-genomic
responses from membrane-associated receptors such as
growth factor receptors and G protein-coupled receptors
[3]. In the last years, a member of the 7-transmembrane
G protein-coupled receptor family, GPR30, has been
identified as a candidate to promote estrogen action in
target cells [4-6] and different investigations have
reported the expression of this novel estrogen receptor in
a large variety of cell types [7]. Furthermore, GPR30 has
been shown to have estrogen-binding affinity and to
mediate estrogen-signal transduction events like calcium
mobilization, kinase activation [5] and rapid transcrip-
tional activation of early genes [8]. Therefore, despite
some controversies regarding its biological role [9],
GPR30 is now widely recognized as an estrogen receptor,
with the new acronym G-protein coupled estrogen recep-
tor GPER, by the International Union of Basic and Clini-
cal Pharmacology [10]
In the human, GPER (GPR30) has been detected n heart,
lung, liver, intestine, ovary, prostate, kidney, brain [11]. In
addition, GPER (GPR30)has been also evidenced in neo-
plastic tissues from breast, endometrial and ovary cancers
[12-14] as well as in breast [15-17], endometrial [18,19]
ovarian [20] and thyroid carcinoma cells lines [21]. How-
ever, the association of the novel estrogen receptor with
human cancer has only recently begun to be defined.
A large body of data indicated that estrogens regulate
testis physiology [1] and they are also involved in male
gonadic diseases, including cancer [22,23]. However,
GPER signaling in human testes is still scarcely known.
Therefore, the aim of this study was to investigate the pat-




The investigation was performed on formalin-fixed and
paraffin-embedded testis tissues from 20 caucasian male
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Leydig cell tumor and 1 Sertoli cell tumor) (ages from
25 to 31 years) and 17 patients with testicular germ cell
tumors (10 seminoma and 7 embryonal carcinoma)
(ages from 20 to 35 years) undergoing to therapeutic
orchidectomy. Non neoplastic testicular tissues were
o b t a i n e df r o m3c a u c a s i a nm a l ep a t i e n t s(a g e sf r o m2 9
to 36 years) showing testes with a granulomatous lesion.
The archival cases were provided by the Pathologic
Anatomy Unit (Annunziata Hospital, Cosenza, Italy).
The ethical committee members of the University of
Calabria approved the investigation programme.
Histopathological analysis
Morphological studies were carried out by Haematoxylin-
Eosin staining.
Chemicals and antibodies
The reagents were purchased from Sigma Aldrich
(Milan, Italy), unless otherwise indicated.
Anti-GPR30 (GPER) primary antibody was rabbit
polyclonal LS-A4271(MBL International Corporation,
Woburn, MA, USA) which recognizes epitope mapped
at the 3
rd extracellular domain of human GPR30. Anti-
human GATA- 4 was goat polyclonal C-20 (Santa Cruz
Biotechnology, Santa Cruz, CA ). Rabbit polyclonal anti
b-actin (Santa Cruz Biotechnology, Ca, USA) was also
used as loading control. Biotinylated goat-anti-rabbit
IgG (Vector Laboratories, INC, Burlingame, CA), bioti-
nylated rabbit- anti -goat (Vector Laboratories, INC,
Burlingame, CA), goat anti-rabbit horseradish peroxi-
dase conjugated IgG (Amersham, USA ) were used as
secondary antibodies.
Immunohistochemical analysis
Paraffin embedded sections, 5 μm thick, were mounted on
slides precoated with poly-lysine, and then they were
deparafinized and dehydrated (7-8 serial sections). Immu-
nohistochemical experiments were performed after heat-
mediated antigen retrieval. Hydrogen peroxide (3% in
distilled water) was used, for 30 minutes, to inhibit endo-
genous peroxidase activity while normal goat serum (10%
) was utilised, for 30 minutes, to block the non-specific
binding sites. Immunodetection was carried out using
anti-GPR30 (GPER) (1:100) primary antibody at 4°C over-
night. Then, a biotinylated goat-anti-rabbit IgG was
applied (1:600) for 1 hour at RT, followed by the avidin-
biotin-horseradish peroxidase complex (ABC/HRP) (Vec-
tor, Laboratories, CA, USA). Immunoreactivity was visua-
lized by using the diaminobenzidine chromogen (DAB)
(Zymed Laboratories, CA, USA). Testis sections were also
counterstained with haematoxylin. The primary antibody
was replaced by normal rabbit serum in negative control
sections. Absorption controls have utilised primary
antibodies preabsorbed with an excess (5 nmol/ml) of the
purified blocking peptide (MBL International Corporation,
Woburn, MA, USA), at 4°C for 48 hours. Breast cancer
tissue was used as positive control.
With the aim to identify the Sertoli cells, sections of
control testes were also subjected to the procedure out-
lined above using anti-human GATA- 4 (1: 50) as primary
antibody.
Scoring system
The immunostained slides of tumour samples were eval-
uated by light microscopy using the Allred Score [24],
which combines a proportion score and an intensity
score. A proportion score was assigned representing the
estimated proportion of positively stained tumor cells
(0 = none; 1 = 1/100; 2 = 1/100 to <1/10; 3 = 1/10 to
<1/3; 4 = 1/3 to 2/3; 5 = >2/3). An intensity score was
assigned by the average estimated intensity of staining
in positive cells (0 = none; 1 = weak; 2 = moderate; 3 =
strong). Proportion score and intensity score were added
to obtain a total score that ranged from 0 to 8. A mini-
mum of 100 cells were evaluated in each slide. Six to
seven serial sections were scored in a blinded manner
for each sample. The one-way ANOVA was used to
evaluate the differences in the scores between tumor
and control samples.
Protein extraction
Protein extraction from formalin-fixed paraffin-embedded
sections was carried out according to Ikeda [25]. Briefly,
50 μm testis sections were deparaffinized in xylene, dehy-
drated in graded ethanol, immersed in distilled water, and
air dried. Then, the selected area was recovered from the
glass slides, further it was cut into small pieces and placed
in Eppendorf tubes. Two hundred μl of RIPA buffer, pH
7,6 (1 M NaH2PO4,1 0m MN a 2HPO4, 154 mM NaCl, 1%
Triton X-100, 12 mM C24H39O4Na, 0,2% NaN3, 0,95 mM
NaF, 2 mM PMSF, 50 mg/ml aprotinin, 50 mM leupeptin)
containing 0,2% SDS, was added to each tube and the con-
tents were incubated at 100°C for 20 minutes, followed by
incubation at 60°C for 2 hours. After incubation, tissue
lysates were centrifuged at 15,000 × g for 20 minutes at
4°C and the supernatants were stored at -80°C until bio-
chemical analysis.
Western blot analysis
Tissue lysates were quantified using Bradford protein assay
reagent [26]. Equal amounts of protein (50 μg) were boiled
for 5 minutes, separated under denaturing conditions by
SDS-PAGE on 10% polyacrylamide Tris-glycine gels and
electroblotted to nitrocellulose membrane. Non-specific
sites were blocked with 5% non fat dry milk in 0.2%
Tween-20 in Tris-buffered saline (TBS-T) for 1 hour at
RT and incubated overnight with anti-GPR30 (GPER)
(1:500), anti-bactin (1:1000) primary antibodies. The
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tion of the membranes for 1 hour at RT with the horse-
radish peroxidase-conjugated secondary antibodies
(1:7000). The bound secondary antibodies were located
with the ECL Plus Western blotting detection system
(Amersham, USA) according to the manufacturer’s
instruction. Each membrane was exposed to the film for
2 minutes. Breast cancer tissue were used as positive con-
trol. Negative controls were prepared using tissue lysates,
where antigens were previously removed by pre-incuba-
tion with specific antibodies (1 hour at room temperature)
and subsequently immunoprecipitated with protein A/G
-agarose.




The unaltered regions of non neoplastic testes were used
as control samples. They displayed typical seminiferous
tubules showing active spermatogenesis. In the basal com-
partment of seminiferous tubules, Sertoli cells were identi-
fied for their typical characteristics: large irregular nuclei
with distinct nucleoli and extensive cytoplasmic processes
extending from the basement membrane to the lumen of
the tubule. Furthermore, Leydig cells were observed in the
interstitial tissue (Figure 1).
In addition to morphological analysis, identification of
Sertoli cells was supported by their dark nuclear staining
of GATA-4, a Sertoli cell marker [27]. Figure 2 shows a
representative comparison between the immunostainings
of GATA-4 (2 A) and GPER (2 B) in two serial sections of
control testis. The same result was observed in all control
samples.
Tumor testes
Sex cord- stromal tumors Leydig cell tumors revealed
large, vacuolated Leydig cells arranged in multiple clusters.
In the Sertoli cell tumor a pattern of diffuse tubular differ-
entiation was observed, while neoplastic cells showed pale
and vacuolated cytoplasms with dysvolumetric and pykno-
tic nuclei (Figure 3)
Testicular germ cell tumors (TGCTs)
Pure seminoma samples showed uniform populations of
round/polygonal big neoplastic cells with well-defined bor-
ders. These cells were arranged in diffuse sheets separated
by thin septae. Extensive leukocyte infiltrations were
observed in all samples (Figure 3). Pure embryonal carci-
nomas revealed nodular areas surrounded by connective
tissue and showing large neoplastic cells with ill-defined
borders, big nuclei, pale cytoplasms (Figure 3)
Immunohistochemistry
The specificity of the GPR30 (GPER) antibody (LS-A4271),
used in the present study, was assessed in previous works
knocking down the protein expression by a shGPR30
(GPER) [19,28-30]. However, similar results were obtained
utilizing the rabbit polyclonal anti-GPR30 (GPER) primary
antibody (sc-48524) from Santa Cruz (Santa Cruz Biotech-
nology, Santa Cruz, CA ) [4,31].
Control testes
GPER immunoreactivity was detected in the cytoplasm of
Leydig cells and Sertoli cells of the control testes while all
germ cells were unlabelled (Figure 1: A, A1, B, B1, C, C1).
Tumor testes
A positive GPER immunostaining was revealed in neo-
plastic cell cytoplasm of Leydig and Sertoli cell tumors
(Figure 4: A-B Leydig cell tumors; C Sertoli cell tumor)
as well as in all seminoma and embryonal carcinoma
samples, while the leukocytes were immunonegative.
(Figure 5: A seminoma, B embryonal carcinoma). Table 1
shows the intensity staining scores of GPER in tumor
and control samples. As expected, a strong GPER signal
was detected in the breast cancer tissue, used as positive
control (5 C). Furthermore, negative controls (data not
shown) and absorption controls (inserts) were all
immunonegative.
Western blot analysis
The immunoblots of testis extracts showed a single band
of ~42 kDa in control (Figure 6: lanes C) and in testicular
germ cell tumor samples (Figure 6: lanes S, EC ) A band at
the same mobility was observed in the positive control
(breast cancer) (Figure 6: lane +), while the negative con-
trol lane was unlabelled (Figure 6: lane -). Similar results
were obtained from all control and TGCT samples. The
quantity of Leydig cell tumor and Sertoli cell tumor sam-
ples was not sufficient to perform the protein extraction
for Western blot analysis.
Discussion
It is well known that estrogens regulate growth, differen-
tiation and function of normal human testes through the
mediation of estrogen receptor beta isoforms (ERb1/ERb2)
[1,32]. In addition, previous studies indicated that the clas-
sical ERs are also involved in the responses to estrogens in
testicular germ cell tumors [33,34] as well as in Leydig cell
tumor [35].
The present study identified GPER in non neoplastic
and neoplastic cells of human male gonads. Particularly,
the “novel” estrogen receptor was localized in the cyto-
plasm of gonadic cells, according to previous observations
showing its presence in the endoplasmic reticulum of dif-
ferent cell types [4,36].
Concerning non neoplastic testes, our investigation
evidenced GPER exclusively in somatic cells, i.e. in
interstitial Leydig cells and in intratubular Sertoli cells.
Particularly, Sertoli cell identification inside seminiferous
tubules was supported by the dark nuclear GATA-4
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expressed in Sertoli cells but not in germ cells of adult
mammals [27]. On the contrary, in the same samples,
GPER immunoreactivity was not observed in germ cells.
Therefore, comparing the cellular distribution of GPER
between human and rodent testes, it appears that GPER
expression is similar in somatic cells but not in germ
cells. In fact, GPER (GPR30) has been found in rat Ser-
toli cells [37] but also in mouse spermatogonia GC-1
cell line [38], in rat pachytene spermatocytes and in rat
round spermatids [39,40]. It is interesting to note that a
similar species- specific expression has been reported
for ERa which has been shown in rat testes[32,41,42]
but not in human testes.
Noteworthy, the present study revealed the expression of
GPER in testis tumors deriving from both somatic and
germ testicular cells. Concerning testicular stromal neo-
plasms, we identified for the first time, GPER in Leydig
cell tumor and Sertoli cell tumor, expanding the limited
knowledge of estrogen signaling mechanism in these rare
neoplasms. Therefore, the present investigation demon-
strated that GPER could mediate estrogen action in both
normal and transformed somatic cells of human testes.
Conversely, our previous study has evidenced a differential
expression pattern of the classical ERs in human normal
Figure 1 Immunolocalization of GPER in control testes. A-C: Positive GPER immunoreactivity in the somatic cell cytoplasm of the three
samples. A1-C1: Higher magnifications of testicular areas surrounded by the dashed lines in A-C. L, Leydig cell; T, seminiferous tubule; S, Sertoli
cell; sg, spermatogonium; sc, spermatocyte; rs, round spermatid; es, elongated spermatid. Inserts: absorption controls. Scale bars = 12.5 μm (A, B,
C), 5 μm (A1, B1,C1).
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ERa in tumor cells, which could amplify estrogen signal-
ing and could contribute to tumor growth [35]
Furthermore, the present investigation demonstrated the
GPER expression in neoplastic cells of seminoma and
embryonal carcinoma. These are testicular germ cell
tumors (TGCTs) deriving from abnormal gonocytes which
arrest their differentiation and undergo a malignant trans-
formation [43-45]. Our previous paper has demonstrated
that ERb1a n dE R b2 could mediate estrogen action in
early and late seminoma and embryonal carcinoma cells
[34] as well as in germ cells of control testes. Conversely,
the present results revealed GPER in the transformed cells
of seminoma and embryonal carcinoma but not in control
Figure 2 Immunostaining of GATA-4 and GPER in control testis (serial sections). A. Dark GATA-4 nuclear immunoreactivity in Sertoli cells
(arrows). B. Dark GPR30 staining in the cytoplasm of Sertoli cells (arrows). Scale bars = 12.5 μm.
Figure 3 Haematoxylin -Eosin staining of representative human testicular tumors. A. Leydig cell tumor. B. Sertoli cell tumor. C. Seminoma.
D. Embryonal carcinoma. Scale bars = 12.5 μm.
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between GPER and testis carcinogenesis. In this regard, a
very recent study [46] have reported the GPR30(GPER)
expression in TGCTs evidencing an increasing expression
of the novel estrogen receptor during the tumor develop-
ment. The authors have suggested GPR30 as a potential
therapeutic target.
Interestingly, it has been reported that estrogens can
contribute to human germ cell cancer proliferation (JKT-
1 seminoma cell line) through a membrane non classical
ER [47]. The same authors have also evidenced that the
xenoestrogen bisphenol A can promote human semi-
noma cell proliferation activating PKA and PKG via a
membrane G-protein-coupled estrogen receptor [48,49]
Different studies have revealed that GPER and the
classical ERs can be co-expressed in some cells, so
synergic/antagonist interactions can be expected on the
basis of the cellular contexts. In this regard, a recent
paper have reported the co-expression of ERb and
(GPR30)GPER in uterine carcinoma together with their
significant correlation during tumor progression [50]. In
the present and our previous studies [34,35] we evi-
denced the expression of either the classical ERs or
GPER in sex-cord stromal and germ cell testicular
tumors, but a possible coordinate regulation or a cross
talk between these estrogen receptors will be clarified by
future investigations performed on neoplastic samples in
early-advanced stages of the disease.
Figure 4 Immunolocalization of GPER in sex cord- stromal testis tumors. A-B: Leydig cell tumors, C:Sertoli cell tumor. Inserts: absorption
controls. Scale bars = 12.5 μm.
Figure 5 Immunolocalization of GPER inTGCTs. A: seminoma. B: embryonal carcinoma. Nc: neoplastic cells. Lc: lymphocytes. C: breast cancer
(positive control). Inserts: absorption controls. Scale bars = 12.5 μm.
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The present investigation identified the cellular expression
of G protein-coupled estrogen receptor (GPER) in non
neoplastic and neoplastic human testes. GPER was
detected exclusively in Leydig cells and Sertoli cells of non
neoplastic testes while it was observed in the transformed
cells of Leydig cell tumor, Sertoli cell tumor, seminoma
and embryonal carcinoma samples. These findings suggest
that GPER could mediate estrogen signaling in both
normal and transformed somatic cells of the human testis,
but at the same time these results reveal a differential
expression of the novel estrogen receptor in normal and
neoplastic germ cells.
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